Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Purchases $96,936.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen purchased 4,200 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the acquisition, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elanco Animal Health Price Performance

ELAN opened at $22.10 on Thursday. The firm has a market cap of $11.04 billion, a PE ratio of -53.90, a P/E/G ratio of 1.36 and a beta of 1.67. The stock has a 50-day moving average price of $24.60 and a 200-day moving average price of $24.04. Elanco Animal Health Incorporated has a 1 year low of $17.11 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. KeyCorp raised their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 31st. TD Cowen lifted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its holdings in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after buying an additional 392 shares during the period. Sapient Capital LLC grew its holdings in shares of Elanco Animal Health by 0.3% in the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after acquiring an additional 420 shares during the period. Lazard Asset Management LLC grew its holdings in shares of Elanco Animal Health by 0.6% in the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC increased its position in Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after acquiring an additional 428 shares during the last quarter. Finally, Meeder Advisory Services Inc. increased its position in Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after acquiring an additional 510 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.